Objective: The study aimed to analyse and report the results of a 'local anaesthesia first' approach in elective endovascular aneurysm repair (EVAR) patients.
Introduction
Endovascular aortic repair (EVAR) has become the first-line treatment option for patients with infrarenal aortic aneurysms. 1, 2 In addition to its surgically 'minimal invasive approach', this treatment modality offers the opportunity of using local (LA) or regional anaesthesia (RA) to potentially further decrease perioperative morbidity and mortality, especially in patients with high significant comorbidities. 3e5 Although feasibility and safety of LA in EVAR has been proven, it still has not become accepted on a large scale as a first-line anaesthetic option and is only applied in a small percentage of EVAR patients (5e10%). 5e10 Reasons include the possibility for optimised imaging and exact placement of the graft, a traditional surgical attitude preferring general anaesthesia (GA) or the fear for either emergency anaesthetic (LA to GA) or surgical conversion (EVAR to open repair) due to intra-operative complications.
The recently published practice guidelines of the Society of Vascular Surgery categorise the level of recommendation and evidence for the use of RA or LA for EVAR as weak or low, respectively. 11 The aim of this study was therefore to report and analyse the results of a unified, 'local anaesthesia first' strategy in a large, prospective and continuous patient cohort of a high-volume EVAR centre.
Methods

Patient population
Between March 1994 and August 2010, endovascular aortic repair of an infrarenal aortic aneurysm was performed in 958 patients. In January 2007, as a result of an institutional commitment to less invasive approaches, we changed our anaesthesia strategy, using LA with monitored anaesthesia care in all patients, while reserving RA defined as spinal or epidural anaesthesia and GA for patients with predefined contraindications (Table 1) . Between January 2007 and August 2010, 217 continuous patients (187 men, median age 76 years, range 52e94 years) underwent elective EVAR with this anaesthetic strategy. LA was used in 183 patients (84%), RA in nine patients (4%) and GA in 25 patients (12%). Patients with symptomatic/ruptured aortic aneurysms, reinterventions after previous EVAR and patients requiring fenestrated stent grafts were excluded from this analysis. For preoperative risk stratification, the patients were scored using the American Society of Anesthesiologists (ASA) classification and the medical co-morbidity grading system suggested by the Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery of the Society for Vascular Surgery/American Association for Vascular Surgery. 12 This medical co-morbidity grading system is a score that involves age and cardiac-, pulmonary-and renal-related risk factors (Level 0/1 Z low/minimal risk to Level 2/3 Z moderate/high-risk level). Baseline characteristics of the patients are presented in Table 2 .
Procedure
All procedures were performed with a team involving vascular surgeons, interventional radiologists and anaesthesiologists in an angiography setting. 13 The following stent grafts were used: Talent (Medtronic, Santa Rosa, CA, USA; n Z 41), Excluder (W.L. Gore & Associates, Flagstaff, AZ, USA; n Z 130), Aneurx (Medtronic; n Z 7), Zenith (Cook, Bloomington, IL, USA; n Z 34), Powerlink (Endologix, Irvine, CA, USA; n Z 3) and Aorfix (Lombard Medical Technologies, Oxfordshire, UK: n Z 2). Percutaneous access was used in 69 access vessels (16%). Additional procedure-specific data are presented in Table 3 . A cell saver is routinely used during all EVAR procedures. This reflects the history of increased blood loss with early devices and sheath that had suboptimal haemostasis and can likely be eliminated based on newer technology.
Anaesthetic management (LA with monitored anaesthesia care)
All preoperative medication (including acetylsalicylic acid and clopidogrel) was continued. Oral anticoagulation with warfarin was stopped, and patients received lowmolecular-weight heparin. Patients had a preoperative fasting period of 8 h. Premedication with 1e2 mg midazolam, an H2 blocker, and glycopyrrolate was administered. A radial arterial line, two 18G peripheral venous catheter and a urinary Foley catheter were placed. Routinely, no central venous catheter was used. Patients received a single dose of cephazolin antibiotic. Intraoperative monitoring included continuous electrocardiogram (ECG), invasive arterial blood pressure, transcutaneous oxygen saturation and urine output. A warming mattress was used. Oxygen was supplied by nasal cannula or mask, if necessary. A restrictive fluid-management concept (1000e1500 ml crystalloids per procedure) was applied. LA was achieved using infiltration of the access sites (lidocaine 2%). For intravenous sedation, propofol was used. Clinical end point of the sedation titration was the minimal amount of propofol that created a still operation field but maintained the airway. If necessary, a fentanyl bolus (50e150 mg IV) for pain treatment was given.
Definitions and statistical analysis
Technical success was defined according to the reporting standards for endovascular aortic aneurysm repair. 14 Endoleaks were categorised as described by White et al. 15 Pulmonary complications were defined as pneumonia, required pharmacological or ventilator support. Renal failure was defined as required temporary or permanent dialysis. 16 A retrospective analysis was performed. Institutional Review Board approval for a retrospective review of the study patients was obtained. Patients were analysed on an intention-to-treat basis. Due to an inherited selection bias of our approach, we report this study as an observational study, focussing on the results of patients undergoing EVAR with LA. Data are expressed as median (range).
Results
Anaesthetic conversion from LA to GA was necessary in 14 patients (7.6%). Airway obstruction (n Z 4) and persistent coughing (n Z 3) were the most common causes for conversion to GA ( Table 4 ). Two of four patients with airway obstructions suffered from previous sleep apnoea. In all LA: Local anesthesia, RA: Regional anesthesia, GA: General anesthesia.
patients with airway-related complications, it was initially tried to lighten the sedation and thus avoid conversion to GA. Patient discomfort (n Z 1), anxiety (n Z 3) and persistent patient movement (n Z 1) preventing exact endograft placement were additional reasons for anaesthesiological conversion. Emergency surgical conversion to open repair was required in two patients (0.9%) due to accidental coverage of the renal arteries (and an additional type I endoleak in one patient), which could not be resolved by endovascular means. Both patients died during the postoperative course (postoperative day 1 and 4) ofmultiorgan failure.
Mortality
The overall 30-day mortality rate was 2.7%, with the five deaths occurring in the LA group. All five patients (median age 85 years) were scored ASA III (n Z 2) or IV (n Z 3) and considered at high cardiac (n Z 3), pulmonary (n Z 3) and renal (n Z 1) risk. Causes of death were multi-organ failure (n Z 2, described above) and influenza-associated pneumonia (one patient with severe pre-existing chronic obstructive pulmonary disease (COPD) requiring constant oxygen therapy). One patient died on the first postoperative day of an unknown cause (autopsy denied by the relatives), but a myocardial infarction was suspected. Intra-operatively, an endoleak of unknown origin (but highly suspicious for a type II) was noticed. The last patient died on the 24th postoperative day of an unknown cause. The operative and postoperative course was uneventful (discharged on day 6). A total of 23 of 217 patients (10.5%) experienced postoperative complications. The complications of all patients are shown in Table 5 . The following paragraph describes the 16 of 183 (8.7%) patients with complications in the LA group:
Systemic complications
Cardiac complications were observed in two patients (myocardial infarction and new onset of atrial fibrillation). Pulmonary complications (n Z 4) included decompensation of a pre-existing COPD requiring oxygen therapy on discharge in two patients, pneumonia and pleural effusion (requiring thoracenteses). Renal complications (n Z 7) included contrast-induced acute or chronic renal failure in three patients and partial embolic renal infarction in one patient. In three of 183 patients (1.6%), accidental coverage of renal arteries occurred and 2 of these 3 patients died post surgical conversion. In one of these 3 patients, the renal arteries were covered by a proximal extension cuff placed for a type I endoleak. In the second patient, proximal migration of the aortic cuff of a Powerlink endograft occurred during endorepair of an endoleak type III. In both patients, repeated attempts to cannulate the renal arteries or pull down the cuff with an inflated LA: Local anesthesia, RA: Regional anesthesia, GA: General anesthesia MOV: multi-organ failure; ICU: intensive care unit. balloon failed, and the patient required surgical conversion. In the third patient, a proximal extension cuff, placed for an endoleak type I, partially covered one renal artery. Catheterisation of the renal artery (including by transbrachial access) failed, and the patient was not considered a candidate for open surgery but did not require dialysis. In retrospect, it could not be evaluated whether these complications were related to patient (e.g., respiratory movements) or technical factors.
Non-systemic complications
Access-related complications were observed in three patients (one groin haematoma and two postoperative occlusion of the access vessel). One patient (no previous aortic surgery, both hypogastric arteries patent) experienced postoperative spinal cord ischaemia (bilateral, new lower-extremity weakness and inability to void), which resolved after spinal-fluid drainage.
Endoleaks
A type I endoleak was observed in five patients (2.7%). All type I endoleaks were observed in the LA group in patients with challenging aneurysm morphologies, including short (<10 mm) landing zones (n Z 3) or angulated (>90 ) necks (n Z 2). Treatment included emergency conversion in one patient (described above). Two small type I endoleaks resolved after 30 days. The other two patients with a type I endoleak are lost to imaging follow-up but currently alive. Intra-operatively, a type III endoleak was seen in one patient. During endorepair, a proximal migration of the stent graft resulting in renal artery coverage occurred and emergency conversion was performed (see above).
Postoperative management
Postoperative pain management (Table 6 ) in patients with LA required the use of opioids (74%), paracetamol (23%) and/or a non-steroidal anti-inflammatory drug (3%). Intensive care unit (ICU) stay was necessary in five of 183 (2.7%) patients, which included two patients after emergency conversion, 1-day surveillance of two high-risk cardiac patients and the patient with spinal cord ischaemia.
Discussion
The present series shows, that a 'local anaesthesia first strategy' can be applied in 85% of the patients undergoing EVAR. It was associated with a relevant anaesthetic conversion (7.6%) and type I endoleak rate (2.7%), leaving approximately 75% of the patients in whom LA can successfully be completed. Consistent with our series, mortality rates after EVAR are reported between 1.2% and 3.7%, and a meta analysis has proven GA as a risk factor (odds ratio (OR) 5.1 95% confidence interval (CI) 1.9e13.3) for death after EVAR. 7,17e19 However, even the few available larger studies that compare LA and RA/GA for EVAR demonstrated no benefit from LA with regard to perioperative mortality (Table 7) , which might be caused by the low mortality rates of current EVAR practice. This requires large patient cohorts to demonstrate a possible effect of LA on perioperative mortality. 7, 16 Regarding perioperative morbidity, different results are reported and summarised in Table 7 . While Verhoeven et al. and the European Collaborators on Stent/Graft Techniques for Aortic Aneurysm Repair (EUROSTAR) Registry report a reduced (especially cardiac related) morbidity for LA, other studies could not demonstrate this effect. 5, 16, 20 However, the study from Verhoeven et al. and the EURO-STAR data overlap a large proportion of patients (177 out of 310 in the LA group), which might explain similar results. Anaesthetic conversion rates from LA to GA vary from 1% to 33% and seem to be lower in centres with more experience in the application of LA. 9, 16, 21, 22 Verhoeven et al. report the lowest anaesthesiological conversion rate of 1%, which compares favourably with our rate of 7.6%. This might be explained by their more rigid contraindications for LA (e.g., body mass index (BMI) > 30), which left 71% of all patients eligible for LA in their series. In our series, LA was applied to 84% of patients and could be completed in 76.4%. A concern of LA is the issue of airway security, especially when sedation is applied. This resulted in anaesthetic conversion in four of 14 patients. Further reasons for conversion included patient movements caused by discomfort or persistent coughing. In addition, many patients were not capable of holding their breath for a prolonged time period. All these factors affect imaging quality in LA and thus precise endograft placement. All type I endoleaks occurred in the LA group in patients with challenging aneurysm morphologies. The use of LA may have meant that we were less able to obtain high-quality imaging to get the optimal proximal seal and, given this experience, we consider extremely challenging anatomies as an additional relative contraindication for LA at present.
Our anaesthesiological strategy resulted in a restrictive fluid management, which might be explained by a high awareness for fluid management caused by the broad application of LA and a low anaesthetic-induced vasodilatation. This series showed a short hospital stay (median 2 days), not only for LA patients, which might reflect rather health-care-related issues than patient-/anaesthesiarelated causes, in our opinion. Other series have reported LA: Local anesthesia, RA: Regional anesthesia, GA: General anesthesia NSAID: non-steroidal anti-inflammatory drug. a significant shortened overall hospital stay (mean 4e6 days in European series) for LA patients. 5, 16 This study cannot provide a cost analysis comparing LA and RA/GA in EVAR. The aforementioned advantages of LA with respect to morbidity, ICU and hospital stay might result in lower costs of LA. However, at present, the discharge time after EVAR is decreasing, and routine ICU stay for EVAR patients has been abandoned in many centres, which might influence costs' analysis. The combination of LA with a percutaneous access seems the next logical step towards an even more minimally invasive treatment. 23 We applied this combination in only 16% of all access vessels but are expanding the use of percutaneous EVAR.
Conclusions
A 'local anaesthesia first' strategy can successfully be applied in 75% of patients undergoing EVAR. The use of LA can impact imaging quality and thus precise endograft placement, which should be considered in patients with challenging aneurysm morphologies. 
